Intensified 14-day rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP14) compared to RCHOP21 in patients with newly diagnosed diffuse large B cell lymphoma (DLBCL): A systematic review and meta-analysis of randomized controlled trials

被引：0
|
作者：
Sandoval-Sus, J. D. [1 ]
Dalia, S. [2 ]
Mhaskar, R. S. [3 ]
Chavez, J. C. [4 ]
Ausekar, A. [5 ]
Purnapatre, K. [5 ]
Scheiber, J. [5 ]
Sokol, L. [4 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Pembroke Pines, FL USA
[2] Mercy Clin, Oncol & Hematol, Joplin, MO USA
[3] Univ S Florida, Internal Med, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL USA
[5] Personome, Munich, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1011PD
引用
收藏
页数：2
相关论文
共 24 条
  • [21] Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy
    Corazzelli, Gaetano
    Frigeri, Ferdinando
    Arcamone, Manuela
    Lucania, Anna
    RosariaVilla, Maria
    Morelli, Emanuela
    Amore, Alfonso
    Capobianco, Gaetana
    Caronna, Antonietta
    Becchimanzi, Cristina
    Volzone, Francesco
    Marcacci, Gianpaolo
    Russo, Filippo
    De Filippi, Rosaria
    Mastrullo, Lucia
    Pinto, Antonio
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2011, 154 (05) : 579 - 589
  • [22] Biweekly Rituximab, Cyclophosphamide, Vincristine, Non-Pegylated Liposome-Encapsulated Doxorubicin (Myocet®) and Prednisone (R-COMP-14) as Induction Treatment in Poor R-IPI Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) and Pre-Existing Heart Disease.
    Frigeri, Ferdi-Nando
    Corazzelli, Gaetano
    Arcamone, Manuela
    Capobianco, Gaetana
    Lucania, Anna
    Becchimanzi, Cristina
    Marcacci, Gianpaolo
    Russo, Filippo
    Villa, Maria Rosaria
    Mastrullo, Lucia
    Pinto, Antonio
    [J]. BLOOD, 2009, 114 (22) : 664 - 664
  • [23] DOSE-DENSE THERAPY WITH NON-PEGYLATED LIPOSOMAL DOXORUBICIN, CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISONE AND RITUXIMAB (R-COMP) IS FEASIBLE AND EFFECTIVE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA: R-COMP 14 VS R-COMP 21. INTERIM ANALYSIS FROM AN ITALIAN MULTICENTE
    Visani, G.
    Ferrara, F.
    Merli, F.
    Angrilli, F.
    Ilariucci, F.
    Falorio, S.
    Fioritoni, G.
    Alesiani, F.
    Brunori, M.
    Pollio, F.
    Celentano, M.
    Cangini, D.
    Ronconi, S.
    Catarini, M.
    Giglio, G.
    Vallisa, D.
    Arcari, A.
    Bernardi, D.
    Guiducci, B.
    Barulli, S.
    Loscocco, F.
    Isidori, A.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 173 - 173
  • [24] First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007
    Fields, P.
    Townsend, W. M.
    Webb, A.
    Pocock, C. F. E.
    Smith, P.
    Kirkwood, A.
    El-Mehidi, N.
    Johnson, P. W.
    Radford, J.
    Linch, D. C.
    Cunningham, D.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 13 - 14
123